Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.

Javier Martín-BrotoNadia HindiGiovanni GrignaniJavier Martinez-TruferoAndres RedondoClaudia ValverdeSilvia StacchiottiAntonio Lopez-PousaLorenzo D'AmbrosioAntonio GutierrezHerminia Perez-VegaVictor Encinas-TobajasEnrique de AlavaPaola ColliniMaria Peña-ChiletJoaquin DopazoIrene Carrasco-GarciaMaria Lopez-AlvarezDavid S MouraJose A Lopez-Martin

Published in: Journal for immunotherapy of cancer (2021)

Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months.Trial registration number NCT03277924.

Keyphrases

end stage renal disease
soft tissue
study protocol
phase iii
renal cell carcinoma
clinical trial
ejection fraction
newly diagnosed
phase ii
chronic kidney disease
metastatic renal cell carcinoma
prognostic factors
cross sectional
high grade
double blind